| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bio-Rad Laboratories (NYSE:BIO) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
Bio-Rad Laboratories beat estimated earnings by 9.93%, reporting an EPS of $3.1 versus an estimate of $2.82.
Revenue was down $49.10 million from the same period last year.
Last quarter the company missed on EPS by $0.45 which was followed by a 7.15% drop in the share price the next day.
Here's a look at Bio-Rad Laboratories's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 2.78 | 2.55 | 3.54 | 3.45 |
| EPS Actual | 2.33 | 3 | 3.34 | 3.31 |
| Revenue Estimate | 689.57M | 687.88M | 689.83M | 742.25M |
| Revenue Actual | 632.12M | 681.10M | 676.84M | 730.29M |
To track all earnings releases for Bio-Rad Laboratories visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BIO
